HIV-protease inhibitor darunavir in the schemes of antiretroviral therapy of the first line
- Autores: Kravchenko AV1, Kravchenko AV1
-
Afiliações:
- Edição: Nº 19 (2009)
- Páginas: 25-30
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278141
- ID: 278141
Citar
Texto integral
Resumo
The results of open-label, randomized comparative phase III trial (ARTEMIS) concerned with evaluation the possibility of use of HIV protease inhibitor Darunavir, "enhanced" by ritonavir (DRV/r) as a component of antiretroviral therapy (ART) of the first line in patients previously not receiving ART, are presented. After 96 weeks of therapy, the ART scheme with DRV/r was more effective than the ART scheme with lopinavir/ritonavir (LPV/r), since the proportion of patients with HIV RNA level below 50 copies/ml were 79 and 71% respectively. The use of DRV/r was more effective in patients with initially high viral load (more than 100 thousand copies/ml) or low number of CD4-lymphocytes (less than 200 cells/ml). ARTEMIS study demonstrated good tolerability of both schemes ART for 96 weeks of treatment. Due to the development of adverse events, treatment was discontinued only in 4% of patients receiving DRV/r, and in 9% of patients receiving LPV/r.
Palavras-chave
Bibliografia
- Клинические рекомендации. ВИЧ-инфекция и СПИД / Под ред. В.В. Покровского. М., 2006. 128 с.
- Кравченко А.В. Дарунавир - ингибитор протеазы ВИЧ нового поколения // Фарматека. 2008. № 19. С. 49-53.
- Кравченко А.В. Современные подходы к началу высокоактивной антиретровирусной терапии и выбор оптимальной схемы лечения первой линии // Фарматека. 2008. № 19. С. 79-83.
- European AIDS Clinical Society Issues New Guidelines for Treatment of HIV October 4, 2008 (http://www.europeanaidsclinicalsociety.org).
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents // Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) November 3, 2008 (http://AIDSinfo.nih.gov <http://aidsinfo.nih.gov/>).
- British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy, 2008 (http://www.bhiva.org/files/file1030835.pdf).
- Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70.
- Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-98.
- Mills A, Nelson M, Jayaweera D, et al. ARTEMIS: efficacy and safety of darunavir/ritonavir 800/100 mg once-daily vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients at 96 wks [abstract no. H-1250c plus poster]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28; Washington, DC.
- Mills AM, Nelson М, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23.
- Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-infected patients at week 48. AIDS 2008;22(12):1389-97.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2464&mid=1085056570&magid=183